Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
VINC 
Vincerx Pharma, Inc. Common Stock (VINC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/09/2025: VINC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $200
1 Year Target Price $200
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 159.37% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.16M USD | Price to earnings Ratio - | 1Y Target Price 200 |
Price to earnings Ratio - | 1Y Target Price 200 | ||
Volume (30-day avg) 2 | Beta 1.68 | 52 Weeks Range 0.03 - 8.20 | Updated Date 10/17/2025 |
52 Weeks Range 0.03 - 8.20 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.79 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -197.53% | Return on Equity (TTM) -3136.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4725287 | Price to Sales(TTM) - |
Enterprise Value -4725287 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.13 | Shares Outstanding 5234277 | Shares Floating 4665573 |
Shares Outstanding 5234277 | Shares Floating 4665573 | ||
Percent Insiders 4.12 | Percent Institutions 5.25 |
Upturn AI SWOT
Vincerx Pharma, Inc. Common Stock
Company Overview
History and Background
Vincerx Pharma, Inc. is a biopharmaceutical company focused on developing and commercializing therapies to treat cancer. Founded in 2019, it has focused on a pipeline of small molecule drug candidates to address unmet medical needs in oncology. Recent milestones include advancing clinical trials for its lead drug candidates.
Core Business Areas
- Drug Development: Focuses on the research and development of small molecule therapeutics for the treatment of cancer.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Commercialization: Plans for the commercialization of approved therapies.
Leadership and Structure
Ahmed Hamdy, M.D., is the Chief Executive Officer. The company operates with a management team overseeing research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- VIP152: VIP152 is an oral small molecule kinase inhibitor targeting cyclin-dependent kinases (CDKs). It is currently in clinical development for hematologic malignancies and solid tumors. Market share data not publicly available as it is not yet commercialized. Competitors are other companies developing CDK inhibitors such as Eli Lilly(Verzenio), Pfizer(Ibrance) , Novartis (Kisqali).
- KD-025 (belumosudil): Vincerx owns royalty rights to KD-025 (belumosudil), commercially marketed as Rezurocku2122. KD-025 is a ROCK2 inhibitor approved for the treatment of chronic graft-versus-host disease (cGVHD). The product is marketed by Kadmon, a wholly owned subsidiary of Sanofi. Market share is significant in the cGVHD segment, but specific figures aren't reported for Vincerx separately. Competitors are other immunosuppressants.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and heavily regulated, with significant R&D costs and long development timelines. Oncology is a major segment with substantial unmet needs and high growth potential.
Positioning
Vincerx Pharma is positioned as a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Its competitive advantage lies in its pipeline of small molecule inhibitors and royalty stream.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. Vincerx is positioned to capture a portion of this TAM through its pipeline and KD-025 royalty rights. Precise TAM calculations are highly variable and depend on specific indications and drug approvals.
Upturn SWOT Analysis
Strengths
- Innovative drug pipeline
- Experienced management team
- KD-025 royalty stream provides funding
- Focus on unmet medical needs in oncology
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from larger pharmaceutical companies
- No guarantee of regulatory approval
Opportunities
- Potential for strategic partnerships
- Expansion of drug pipeline
- Positive clinical trial results
- Acquisition or licensing of new technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- LLY
- PFE
- NVS
- MRTX
- GILD
Competitive Landscape
Vincerx faces competition from established pharmaceutical companies with greater resources. Its pipeline represents a competitive advantage if the drug candidates prove effective and receive regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily measured by advancements in the drug pipeline and financial performance as a developmental-stage company.
Future Projections: Future projections depend on the success of clinical trials, regulatory approvals, and commercialization efforts. Analyst estimates can be found on financial news and data provider websites.
Recent Initiatives: Recent initiatives include advancing clinical trials for VIP152.
Summary
Vincerx Pharma is a clinical-stage biopharmaceutical company with a pipeline of oncology therapeutics and a royalty stream. Its success hinges on positive clinical trial results and regulatory approvals. While the pipeline and royalty provide some stability, the company faces significant financial risks and competition. Vincerx must execute its clinical programs effectively to create long-term shareholder value. Clinical trial results and securing partnerships are key considerations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Vincerx Pharma, Inc. SEC Filings
- Company Press Releases
- Financial News Providers
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Data and projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vincerx Pharma, Inc. Common Stock
Exchange NASDAQ | Headquaters San Mateo, CA, United States | ||
IPO Launch date 2020-05-27 | Co-Founder, Acting CEO, Secretary & Director Dr. Raquel E. Izumi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://vincerx.com |
Full time employees 12 | Website https://vincerx.com | ||
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.